Mental Health Center Sofia EOOD
- Address
- Bulevard Slivnitsa 309, 1202 Sofia, Bulgaria
Depression and Mood Disorders
The Mental Health Center Sofia EOOD conducts extensive studies on Major Depressive Disorder and related mood conditions, aiming to improve treatment options for patients who have not responded adequately to standard antidepressants.
- Adjunctive novel compounds
- Anhedonia‑targeted interventions
- Anxious distress sub‑analyses
- Long‑term safety extensions
Across 12 trials, eight investigators evaluate new therapeutic approaches, enhancing care for individuals with depression in Sofia, Bulgaria.
Schizophrenia and Psychotic Disorders
Research at the site focuses on Schizophrenia, testing adjunctive agents to reduce persistent symptoms and assess tolerability over extended periods.
- Positive and Negative Syndrome Scale (PANSS) outcomes
- Adjunctive antipsychotic strategies
- Oral long‑acting formulations
- Safety monitoring in chronic use
The department’s expertise in severe mental illness supports innovative trials that may reshape standard care for schizophrenia patients.
Neuropsychiatric Symptoms in Alzheimer’s Disease
A subset of studies addresses agitation linked to Alzheimer’s disease, evaluating rapid‑acting combinations to calm patients while maintaining safety.
- CMAI‑IPA agitation scoring
- Combination therapy with KarXT + KarX‑EC
- Open‑label extension for durability
- Safety profiling in elderly cohorts
These investigations broaden the Center’s portfolio beyond primary psychiatric disorders, reflecting a commitment to comprehensive behavioral health research.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 of 3 therapeutic areas and 15 of 27 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
lock +9 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB4trials
lock +5 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 476 other sites in Bulgaria
Therapeutic Area Benchmark — Bulgaria
Select a therapeutic area to compare against other sites in Bulgaria.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Bulgaria
Market Share
Country: Bulgaria
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Mental Health Center Sofia EOOD
lock Showing 1 of 24 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of DT-101 in Adults with Major Depressive Disorder | Draig Therapeutics Limited | Phase II | Recruiting | Mar 2026 | — |
IMP list
lock Showing 1 of 27 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Trospium Chloride | 4 | Unknown | 2023-03-22 | 2026-06-01 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.